drugset

drugset / Trial / NCT05202860

Impact of Human Papillomavirus (HPV) Vaccination on Burden of Disease in Patients with Actinic Keratosis

NCT05202860 ↗

Phase 2 Active not recruiting 70 enrolled Merete Haedersdal

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double-blind, randomized, placebo controlled intervention trial on patients with actinic keratosis.

Timeline

Start: 2022-05-09
Primary completion: 2024-06-19
Completion: 2034-06-19

Publications

Wenande E, Hastrup A, Wiegell S, Philipsen PA, Thomsen NB, Demehri S, Kjaer SK, Haedersdal M. Human Papillomavirus Vaccination and Actinic Keratosis Burden: The VAXAK Randomized Clinical Trial. JAMA Dermatol. 2025 Jun 1;161(6):605-614. doi: 10.1001/jamadermatol.2025.0531.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gardasil 9	Vaccine	—	Intramuscular

Indications